Literature DB >> 14527502

Landau-Kleffner syndrome responsive to levetiracetam.

Eric H Kossoff1, Dana Boatman, John M Freeman.   

Abstract

A 5-year-old girl with Landau-Kleffner syndrome is discussed. The child began having seizures at age 4 associated with language deterioration despite anticonvulsant therapy. With levetiracetam monotherapy to a dose of 60 mg/kg/day and discontinuation of carbamazepine and valproic acid, her language has improved and seizures are controlled. Levetiracetam should be considered as therapy for Landau-Kleffner syndrome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14527502     DOI: 10.1016/s1525-5050(03)00171-9

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  5 in total

Review 1.  Benefit-risk assessment of levetiracetam in the treatment of partial seizures.

Authors:  Bassel Abou-Khalil
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  Management of Landau-Kleffner syndrome.

Authors:  Mohamad A Mikati; Alhan N Shamseddine
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 3.  Levetiracetam Monotherapy in Children with Epilepsy: A Systematic Review.

Authors:  Amerins Weijenberg; Oebele F Brouwer; Petra M C Callenbach
Journal:  CNS Drugs       Date:  2015-05       Impact factor: 5.749

4.  Levetiracetam in the treatment of epilepsy.

Authors:  Bassel Abou-Khalil
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

5.  Efficacy of Levetiracetam in Treatment of Childhood Stuttering.

Authors:  Mohammadreza Ghazavi; Fateme Rastgu; Jafar Nasiri; Omid Yaghini
Journal:  Int J Prev Med       Date:  2020-02-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.